Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | XBP1 | P17861 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | SLC13A3 | Q8WWT9 | 1/20 | 0.44 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2095417 | 0.96 | L3MBTL1 (0.58) | L3MBTL1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL11656945 | 0.89 | SMN1; SMN2 (0.60) | MAPTMEN1KMT2ASMN1; SMN2HPGD | |
| SCHEMBL9630497 | 0.87 | GRM4 (0.49) | L3MBTL1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3786311 | 0.80 | KDM4E (0.60) | L3MBTL1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1188370 | 0.80 | HPGD (0.71) | MAPTMEN1KMT2ASMN1; SMN2HPGD | |
| SCHEMBL3786493 | 0.80 | L3MBTL1 (0.44) | L3MBTL1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL31153302 | 0.79 | MAPT (0.53) | MAPTMEN1KMT2ASMN1; SMN2HPGD | |
| SCHEMBL6200925 | 0.79 | MEN1 (0.51) | L3MBTL1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3786021 | 0.79 | SMN1; SMN2 (0.64) | L3MBTL1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1188088 | 0.78 | SMN1; SMN2 (0.67) | L3MBTL1MAPTMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | L3MBTL1 3838/4885MAPT 3312/4885MEN1 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.